| First Author | Moschovakis GL | Year | 2019 |
| Journal | Cell Mol Immunol | Volume | 16 |
| Issue | 10 | Pages | 791-799 |
| PubMed ID | 29973648 | Mgi Jnum | J:319387 |
| Mgi Id | MGI:6823115 | Doi | 10.1038/s41423-018-0056-5 |
| Citation | Moschovakis GL, et al. (2019) The chemokine receptor CCR7 is a promising target for rheumatoid arthritis therapy. Cell Mol Immunol 16(10):791-799 |
| abstractText | The chemokine receptor CCR7 and its ligands CCL19 and CCL21 guide the homing and positioning of dendritic and T cells in lymphoid organs, thereby contributing to several aspects of adaptive immunity and immune tolerance. In the present study, we investigated the role of CCR7 in the pathogenesis of collagen-induced arthritis (CIA). By using a novel anti-human CCR7 antibody and humanized CCR7 mice, we evaluated CCR7 as a target in this autoimmune model of rheumatoid arthritis (RA). Ccr7-deficient mice were completely resistant to CIA and presented severely impaired antibody responses to collagen II (CII). Selective CCR7 expression on dendritic cells restored arthritis severity and anti-CII antibody titers. Prophylactic and therapeutic treatment of humanized CCR7 mice with anti-human CCR7 mAb 8H3-16A12 led to complete resistance to CIA and halted CIA progression, respectively. Our data demonstrate that CCR7 signaling is essential for the induction of CIA and identify CCR7 as a potential therapeutic target in RA. |
